Sangamo Therapeutics, Inc. - Common Stock (SGMO)
Frequently Asked Questions About Sangamo Therapeutics, Inc. - Common Stock (SGMO)
How can investors learn more about Sangamo?
Investors can learn more about Sangamo Therapeutics by visiting the company's official website, where they can access investor relations materials, including financial reports, news releases, and updates on clinical progress. Additionally, the company often participates in investor conferences and presentations, providing further insights into its business strategies and pipeline developments.
How does Sangamo approach regulatory compliance?
Sangamo Therapeutics prioritizes regulatory compliance by adhering to guidelines set forth by the U.S. Food and Drug Administration (FDA) and other global regulatory agencies. The company conducts its research and clinical trials in alignment with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) to ensure the highest standards of quality and safety in its developmental processes.
How does Sangamo engage with the patient community?
Sangamo Therapeutics actively engages with the patient community through outreach initiatives, educational programs, and partnerships with patient advocacy groups. The company seeks to foster open communication and collaboration, ensuring that patient voices are considered in the development of its therapies and clinical research efforts.
How does Sangamo's technology differ from CRISPR?
Sangamo's zinc finger protein (ZFP) technology differs from CRISPR-Cas9 in its approach to gene editing. While CRISPR utilizes RNA-guided nucleases for targeting, ZFP employs engineered proteins that bind specifically to DNA sequences, resulting in precise modifications. This approach aims to minimize off-target effects and enhance safety in therapeutic applications.
Is Sangamo listed on the stock market?
Yes, Sangamo Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol SGMO. Being a publicly traded company offers Sangamo access to capital markets for funding its research and development initiatives, allowing it to advance its innovative therapeutic programs.
What are Sangamo's main therapeutic areas of focus?
Sangamo Therapeutics focuses on several key therapeutic areas, including genetic disorders, hemophilia, central nervous system disorders, and oncology. The company aims to develop pioneering gene editing and gene therapy solutions that have the potential to significantly impact patients' lives by addressing the root causes of these diseases.
What are the goals of Sangamo's research programs?
The goals of Sangamo's research programs are to develop novel genomic therapies that can provide safe, effective, and durable cures for patients with genetic disorders. By pioneering innovative technologies and approaches, the company seeks to deliver transformative healthcare solutions while advancing scientific knowledge in gene therapy and editing.
What are the potential risks associated with Sangamo's therapies?
Potential risks associated with Sangamo's therapies include off-target gene editing, immune responses to the therapeutic agents, and unknown long-term effects of gene modifications. As with any investigational therapies, clinical trials are designed to monitor these risks carefully, ensuring patient safety as the company advances towards commercialization.
What challenges does Sangamo face in the biotechnology industry?
Sangamo Therapeutics faces several challenges in the biotechnology industry, including regulatory hurdles, competition from other companies working on similar technologies, and the necessity for securing funding for ongoing research and clinical trials. Additionally, demonstrating the long-term efficacy and safety of its therapies is critical for gaining market approval and acceptance within the medical community.
What clinical trials are currently ongoing at Sangamo?
Sangamo Therapeutics is conducting multiple clinical trials across its pipeline of gene editing and therapy programs. These trials investigate treatments for conditions such as hemophilia A and B, neurodegenerative diseases, and genetic disorders like Hunter syndrome. The trials vary in phase, with some focusing on initial safety and dosage, while others assess efficacy and long-term outcomes.
What does Sangamo Therapeutics, Inc. do?
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company specializing in gene therapy, gene editing, and cell therapy programs. The company utilizes its proprietary zinc finger protein technology to develop innovative treatments for a variety of genetic disorders, hemophilia, neurodegenerative diseases, and cancer. With a focus on advancing precise genomic medicines, Sangamo aims to provide transformative therapies that can address unmet medical needs.
What is Sangamo's mission statement?
Sangamo Therapeutics' mission is to leverage its innovative gene editing and gene therapy technologies to develop transformative medicines that address severe and life-altering diseases. The company aims to improve patient outcomes and quality of life by pioneering scientific advancements in genomic medicine.
What is Sangamo's pipeline of therapies?
Sangamo Therapeutics has a diverse pipeline of therapies, with programs targeting hemophilia, genetic disorders, and neurodegenerative diseases. The pipeline includes both early-stage and late-stage clinical programs, showcasing the company’s commitment to advancing multiple therapeutic solutions for various indications within the realm of gene therapy and editing.
What is the role of Sangamo's leadership team?
The leadership team at Sangamo Therapeutics plays a crucial role in shaping the company's vision and strategic direction. Comprising experienced professionals from the biotechnology and pharmaceutical sectors, the team is responsible for guiding research initiatives, managing clinical development programs, and driving business operations to achieve the company's goals.
What is the significance of gene therapy in Sangamo's work?
Gene therapy is a key component of Sangamo's research and development efforts, as it provides a means to address genetic disorders at their source. By correcting or replacing faulty genes, Sangamo's gene therapy approaches aim to cure diseases or significantly alleviate their symptoms, potentially changing the standard of care for various conditions.
What technologies does Sangamo use in its research?
Sangamo utilizes proprietary zinc finger protein (ZFP) technology, which enables the precise editing and regulation of genes. This technology allows for targeted gene modifications, offering potential solutions for a variety of genetic disorders and diseases. Additionally, the company is involved in developing therapies that leverage electroporation and other delivery systems for effective gene therapy applications.
What was a recent milestone for Sangamo?
Recently, Sangamo achieved a significant milestone with the advancement of its clinical trials for its hemophilia therapies. Positive initial results demonstrating safety and efficacy have propelled the company's lead programs into later stages of clinical development, reinforcing Sangamo's position as a leader in the gene therapy space.
Where is Sangamo Therapeutics headquartered?
Sangamo Therapeutics is headquartered in Brisbane, California. This strategic location allows the company to collaborate with leading research institutions and partners in the biotechnology hub of the Bay Area, facilitating innovation and development in gene therapy and editing technologies.
Who are Sangamo's partners in research and development?
Sangamo collaborates with various pharmaceutical and biotechnology companies, as well as academic institutions, to advance its research and development initiatives. Notable partnerships include collaborations with companies like Pfizer, which focuses on hemophilia therapies, and others that support the development of gene therapies across different therapeutic areas.
What is the current price of Sangamo Therapeutics, Inc. - Common Stock?
The current price of Sangamo Therapeutics, Inc. - Common Stock is 0.6532
When was Sangamo Therapeutics, Inc. - Common Stock last traded?
The last trade of Sangamo Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Sangamo Therapeutics, Inc. - Common Stock?
The market capitalization of Sangamo Therapeutics, Inc. - Common Stock is 94.93M
How many shares of Sangamo Therapeutics, Inc. - Common Stock are outstanding?
Sangamo Therapeutics, Inc. - Common Stock has 145.34M shares outstanding.